Mottola Frank 4
4 · SUPERNUS PHARMACEUTICALS, INC. · Filed Dec 22, 2025
Insider Transaction Report
Form 4
Mottola Frank
SVP, Chief Tech. Ops. Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-19$39.40/sh+5,000$197,000→ 20,496 total - Sale
Common Stock
2025-12-19$50.22/sh−5,000$251,100→ 15,496 total - Exercise/Conversion
Common Stock
2025-12-19$25.30/sh+15,000$379,500→ 30,496 total - Sale
Common Stock
2025-12-19$50.47/sh−15,000$757,050→ 15,496 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2025-12-19−5,000→ 0 totalExercise: $39.40Exp: 2028-02-14→ Common Stock (5,000 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2025-12-19−15,000→ 0 totalExercise: $25.30Exp: 2027-02-24→ Common Stock (15,000 underlying)
Footnotes (5)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.39. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.69. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F4]The option vests in four equal annual installments beginning on February 14, 2019 .
- [F5]The option vests in four equal annual installments beginning on February 24, 2018.